<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A controlled clinical study on disodium cromoglycate (DSCG) at a dose of 800 mg per day versus placebo was carried out in 141 patients with <z:hpo ids='HP_0100279'>ulcerative colitis</z:hpo> and 25 patients with <z:hpo ids='HP_0100280'>Crohn's disease</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Those of the <z:hpo ids='HP_0100279'>ulcerative colitis</z:hpo> patients who had been on sulphasalazine treatment continued that treatment during the trial (101 patients) </plain></SENT>
<SENT sid="2" pm="."><plain>Forty patients were intolerant of sulphasalazine </plain></SENT>
<SENT sid="3" pm="."><plain>No patient received steroids during the last month before the study </plain></SENT>
<SENT sid="4" pm="."><plain>Patients with <z:hpo ids='HP_0100280'>Crohn's disease</z:hpo> had their possible sulphasalazine treatment stopped before the trial </plain></SENT>
<SENT sid="5" pm="."><plain>No beneficial effect of DSCG as compared with placebo was found, as the DSCG and the placebo group showed the same number of relapses in patients with a clinically inactive <z:hpo ids='HP_0100279'>ulcerative colitis</z:hpo> at the start of the trial and the same number of patients improving, deteriorating, and maintaining steady state in patients with clinically active <z:hpo ids='HP_0100279'>ulcerative colitis</z:hpo> at the start of the trial </plain></SENT>
<SENT sid="6" pm="."><plain>There was no difference between relapse rate in DSCG and placebo groups in patients with <z:hpo ids='HP_0100280'>Crohn's disease</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>No correlation between the eosinophil count in rectal mucosa and the outcome of the attack of <z:hpo ids='HP_0100279'>ulcerative colitis</z:hpo> could be demonstrated </plain></SENT>
</text></document>